The observed adherence rate to PSA screening for prostate cancer has decreased from 64.6% to 1999 to 39.0% in 2008 due to the concerns of overdiagnosis and lack of evidence on the improvement in outcomes. This evidence concerns the gene KLK3 and prostate cancer.